Be Biopharma has ended its clinical trial testing a novel cell therapy for hemophilia B, according to a disclosure the company made in a federal clinical trials listing first reported by Endpoints News.
The therapy was designed using a patient's own cells — a category known as B cell therapy — modified through gene editing. Rather than introducing a corrected gene via a viral vector, as most hemophilia gene therapies do, Be Bio's approach reprogrammed B cells to produce the clotting factor that hemophilia B patients lack.
According to Endpoints News, the termination was disclosed quietly through the federal clinical trials registry, not through a press announcement.
Hemophilia B is a rare inherited bleeding disorder caused by insufficient levels of clotting factor IX. People with the condition can suffer dangerous internal bleeding from minor injuries, and many rely on regular infusions of the missing protein. A durable, one-time cell or gene therapy has long been seen as a potential cure — making the failure of any serious clinical candidate a setback for patients hoping to move beyond lifelong treatment.
The collapse of this trial is a reminder of how difficult it remains to translate promising cell engineering science into a working medicine — and narrows the field of novel approaches being tested for a disease that desperately needs better options.